|Ribomunyl, Immucytal, Ribovac||ARN extraction, ribosomal fractions||4 strains : Klebsiella pneumoniae Streptococcus |
Streptococcus pyogenes, Haemophilus
|Oral||1 unit for 4 days per week during 3 weeks, then for 4 days/month during the cold season|
|Pulmonarom||No documentation available||9 strains :|
Haemophilus influenzae, Staphylococcus aureus, Moraxella catarrhalis, Klebsiella pneumoniae, Diplococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus
|Oral||1 vial of 3 ml per day, 10 days a month, for 2 months|
|Chemical lysis, soluble antigens||8 strains :|
|Oral||1 capsule/Day 10 days a month, during 3 months|
|Luivac, Paspat||No documentation available||7 strains :|
Streptococcus mitis (viridans),
|Oral||1 tablet/day for one month (28D), stop one month and another course of 1 tablet/day for one month (28D)|
|Mechanical lysis documented, particulate antigens||13 strains :|
Streptococcus oralis (formerly viridans),
Neisseria (formerly Moraxella) catarrhalis,
Streptococcus (formerly Diplococcus) pneumoniae (Type 1, Type 2, Type 3, Type 5, Type 8, Type 47)
|Sublingual||1 tablet/day, 10 days a month, during 3 months|
Lallemand Pharma AG, based in Massagno (Switzerland) is a company dedicated to the development and commercialization of respiratory products having the status of drug or medical device.
Since 2007, Lallemand Pharma markets drugs containing as an active principle, a bacterial lysate called PMBL®. Products are sold in several countries under different brands Ismigen®, Immubron®, Respibron® and PIR-05®. PMBL based products are Rx products indicated in the prevention and treatment of recurrent respiratory tract infections.
In 2018, Lallemand Pharma started to develop a line of nasal sprays also aiming at respiratory conditions.
All nasal sprays contain an active ingredient called Symbiofilm®.Symbiofilm® is an exoplymeric substance able to slow down the turnover of the biofilm built by most of the pathogenic bacteria having a respiratory tropism. Symbiofilm® also reduces the attachment of respiratory viruses on the nasal mucosa.
The line of nasal sprays is called Healsea® and can be proposed either with a bag on valve technology or with manual spray pump. Both lines obtained their CE marking allowing commercialization all over Europe in April 2021.
Willing to improve the quality of life of every individual in every season, all lifelong, in the field of respiratory health, Lallemand Pharma consistently invests in scientific research.
Through a dual expertise in immunity and respiratory field, Lallemand Pharma is committed to bring to its pharmaceutical partners and customers, quality immunostimulant drugs, innovative medical device, and services.
One of our missions is to ensure a continuous education of the healthcare as well as patients’ communities about the importance of respiratory health and immunization.
Lallemand Pharma has built an international network of key experts in immunity and respiratory medicines.
Because oxygen and breathing are fuel for life and mind, it is our duty to protect it! Respire, Inspire!
Linked to the mission of Lallemand Pharma to focus its attention to the respiratory and immunostimulant fields, our values have always been to :
- Respect and listen to the needs of our pharmaceutical partners
- Bring the best services and supports to our partners, thanks to our dedicated Regulatory Affairs, Pharmacovigilance, Supply/Customer services, and Marketing departments.
- Facilitate the exercise of every healthcare practitioner in the information to patients
- Develop scientific information and communities about immunization and respiratory health
At Lallemand Pharma, patients will always remain at the center of our attention.